Neonatal anemia

Summary

Neonatal anemia (MONDO:0001240) is a disease and 7 clinical trials. A subtype of anemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neonatal anemia
Mondo ID	MONDO:0001240
MeSH	D000751
DOID	DOID:11244
SNOMED CT	234350007
UMLS	C0002891
MedGen	1530
Is cancer (heuristic)	no

Also known as: anemia neonatal

Disease family

This is a subtype of anemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › hematologic disorder › anemia › neonatal anemia

Related subtypes (18): congenital anemia, microcytic anemia, hypochromic anemia, pancytopenia, deficiency anemia, pure red-cell aplasia, macrocytic anemia, normocytic anemia, sideroblastic anemia, aplastic anemia, hemoglobin C disease, hemoglobin E disease, beta-thalassemia and related diseases, hemoglobinopathy Toms River, hereditary methemoglobinemia, hemoglobin D disease, anemia due to enzyme disorder, anemia due to chronic disorder

Subtypes (3): anemia of prematurity, kernicterus due to isoimmunization, twin to twin transfusion syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

No drug has an approved disease-direct ChEMBL indication for this disease.

2 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

Drug	Highest phase
Biotin	Phase 2
Epoetin Alfa	Phase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00731588	PHASE2	COMPLETED	Red Blood Cell (RBC) Survival Following Transfusion in Infants
NCT02075970	PHASE2	COMPLETED	Optimized Erythropoietin (EPO) Treatment
NCT06285604	Not specified	ACTIVE_NOT_RECRUITING	Effect Evaluation of Different Blood Products Infusion on Neonatal Anemia
NCT07502781	Not specified	NOT_YET_RECRUITING	Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants
NCT01232387	Not specified	COMPLETED	Identification of Early Predictors of Fetomaternal Hemorrhage
NCT02454101	Not specified	COMPLETED	Milking Versus Delayed Cord Clamping in Full Term Neonates
NCT03624335	Not specified	COMPLETED	Influence of Umbilical Cord Clamping Time in the Newborn